Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Change in Cash (2022 - 2025)

Historic Change in Cash for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $20.8 million.

  • Entrada Therapeutics' Change in Cash rose 11940.6% to $20.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.2 million, marking a year-over-year decrease of 4177.02%. This contributed to the annual value of $33.6 million for FY2024, which is 4973.94% up from last year.
  • Latest data reveals that Entrada Therapeutics reported Change in Cash of $20.8 million as of Q3 2025, which was up 11940.6% from $4.6 million recorded in Q2 2025.
  • Over the past 5 years, Entrada Therapeutics' Change in Cash peaked at $182.5 million during Q1 2023, and registered a low of -$202.5 million during Q1 2022.
  • For the 4-year period, Entrada Therapeutics' Change in Cash averaged around -$12.9 million, with its median value being $834000.0 (2024).
  • In the last 5 years, Entrada Therapeutics' Change in Cash skyrocketed by 29278.88% in 2023 and then plummeted by 410167.87% in 2025.
  • Over the past 4 years, Entrada Therapeutics' Change in Cash (Quarter) stood at -$8.2 million in 2022, then soared by 292.79% to $15.7 million in 2023, then soared by 47.34% to $23.2 million in 2024, then decreased by 10.18% to $20.8 million in 2025.
  • Its Change in Cash stands at $20.8 million for Q3 2025, versus $4.6 million for Q2 2025 and -$33.4 million for Q1 2025.